| pubmed-article:6419761 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6419761 | lifeskim:mentions | umls-concept:C0040128 | lld:lifeskim |
| pubmed-article:6419761 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:6419761 | lifeskim:mentions | umls-concept:C0029997 | lld:lifeskim |
| pubmed-article:6419761 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:6419761 | pubmed:dateCreated | 1984-3-6 | lld:pubmed |
| pubmed-article:6419761 | pubmed:abstractText | The pharmacokinetics of oxazepam, a drug mainly eliminated by a single step glucuronidation reaction, were studied in seven hyperthyroid and six hypothyroid patients before and after treatment. Oxazepam elimination half-life was shorter and apparent oral clearance higher in untreated hyperthyroid patients than after treatment. There was no significant change in oxazepam elimination in hypothyroid subjects. Time to peak concentration (tmax) was reduced in the hyperthyroid state. Hypothyroidism had no significant effect on tmax. Serum bilirubin concentration was lower in the patients while hyperthyroid before treatment than when euthyroid and also lower than in the hypothyroid patients. There was no significant correlation between serum bilirubin concentrations and oxazepam elimination. These results suggest that glucuronyl transferase activity is increased in hyperthyroidism but is not altered in most patients with hypothyroidism. The extent of increase in glucuronyl transferase activity is similar to that produced by enzyme inducing drugs. | lld:pubmed |
| pubmed-article:6419761 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6419761 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6419761 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6419761 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6419761 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6419761 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6419761 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6419761 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6419761 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6419761 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6419761 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6419761 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6419761 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6419761 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6419761 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6419761 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6419761 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6419761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6419761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6419761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6419761 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6419761 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:6419761 | pubmed:issn | 0306-5251 | lld:pubmed |
| pubmed-article:6419761 | pubmed:author | pubmed-author:HoltS JSJ | lld:pubmed |
| pubmed-article:6419761 | pubmed:author | pubmed-author:BewsherP DPD | lld:pubmed |
| pubmed-article:6419761 | pubmed:author | pubmed-author:ScottA KAK | lld:pubmed |
| pubmed-article:6419761 | pubmed:author | pubmed-author:HawksworthG... | lld:pubmed |
| pubmed-article:6419761 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6419761 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:6419761 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6419761 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6419761 | pubmed:pagination | 49-53 | lld:pubmed |
| pubmed-article:6419761 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:6419761 | pubmed:meshHeading | pubmed-meshheading:6419761-... | lld:pubmed |
| pubmed-article:6419761 | pubmed:meshHeading | pubmed-meshheading:6419761-... | lld:pubmed |
| pubmed-article:6419761 | pubmed:meshHeading | pubmed-meshheading:6419761-... | lld:pubmed |
| pubmed-article:6419761 | pubmed:meshHeading | pubmed-meshheading:6419761-... | lld:pubmed |
| pubmed-article:6419761 | pubmed:meshHeading | pubmed-meshheading:6419761-... | lld:pubmed |
| pubmed-article:6419761 | pubmed:meshHeading | pubmed-meshheading:6419761-... | lld:pubmed |
| pubmed-article:6419761 | pubmed:meshHeading | pubmed-meshheading:6419761-... | lld:pubmed |
| pubmed-article:6419761 | pubmed:meshHeading | pubmed-meshheading:6419761-... | lld:pubmed |
| pubmed-article:6419761 | pubmed:meshHeading | pubmed-meshheading:6419761-... | lld:pubmed |
| pubmed-article:6419761 | pubmed:meshHeading | pubmed-meshheading:6419761-... | lld:pubmed |
| pubmed-article:6419761 | pubmed:meshHeading | pubmed-meshheading:6419761-... | lld:pubmed |
| pubmed-article:6419761 | pubmed:year | 1984 | lld:pubmed |
| pubmed-article:6419761 | pubmed:articleTitle | Oxazepam pharmacokinetics in thyroid disease. | lld:pubmed |
| pubmed-article:6419761 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6419761 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6419761 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6419761 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6419761 | lld:pubmed |
